Urica Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2021-01-01
- Employees
- 1
- Market Cap
- -
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
Phase 1
Completed
- Conditions
- HyperuricemiaGout
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Urica Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06056570
- Locations
- 🇺🇸
Southwest Rheumatology Research, Mesquite, Texas, United States
🇺🇸Endeavor Clinical Trials, San Antonio, Texas, United States
🇺🇸Clinical Research of West Florida, Clearwater, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath